HiveProspectBiotech Decision IntelligenceLive

Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

Refine the decision · 12 filters (subscription required)
Reset filters

1 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · TERMINATED

JMT103

Hypercalcemia of Malignancy

Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

SOURCE FACT Due to a change in the company's research strategy

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity
Source, stopping context and uncertainty

Due to a change in the company's research strategy

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source